NCT01532700 2019-09-24
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
5 trialsNCT01531894 2019-07-09
Continuation Study of the Oral AKT Inhibitor GSK2110183
Novartis
Phase 2 Completed
NCT01428492 2018-08-08
PKB115125
Novartis
Phase 1 Completed
NCT01653912 2018-04-02
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Accenture
Phase 1/2 Completed
NCT01476137 2017-11-13
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
GlaxoSmithKline
Phase 1 Completed